Immune Design Corp (IMDZ) Receives Average Recommendation of “Hold” from Brokerages

Shares of Immune Design Corp (NASDAQ:IMDZ) have received a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $16.00.

Several analysts recently issued reports on the company. ValuEngine downgraded Immune Design from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and cut their target price for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Immune Design in a research note on Monday, December 11th.

In other news, CEO Carlos V. Paya sold 7,970 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.17, for a total value of $33,234.90. Following the sale, the chief executive officer now owns 114,560 shares of the company’s stock, valued at approximately $477,715.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Leo Guthart acquired 10,000 shares of the company’s stock in a transaction dated Thursday, October 19th. The stock was purchased at an average cost of $6.09 per share, for a total transaction of $60,900.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 5,310,000 shares of company stock worth $21,855,900 and have sold 13,959 shares worth $58,209. 20.70% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of IMDZ. Alliancebernstein L.P. bought a new stake in shares of Immune Design in the 2nd quarter worth $118,000. Virtu KCG Holdings LLC bought a new stake in shares of Immune Design in the 2nd quarter worth $153,000. Dimensional Fund Advisors LP raised its stake in shares of Immune Design by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Immune Design by 53.9% in the 2nd quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after buying an additional 6,896 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Immune Design by 95.1% in the 2nd quarter. New York State Common Retirement Fund now owns 20,100 shares of the biotechnology company’s stock worth $196,000 after buying an additional 9,799 shares in the last quarter. 29.34% of the stock is currently owned by institutional investors.

Shares of Immune Design (NASDAQ IMDZ) opened at $3.60 on Wednesday. The stock has a market capitalization of $173.01, a P/E ratio of -1.69 and a beta of 2.36. Immune Design has a 1-year low of $3.50 and a 1-year high of $13.05.

Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.11. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. sell-side analysts anticipate that Immune Design will post -1.89 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Immune Design Corp (IMDZ) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/17/immune-design-corp-imdz-receives-average-recommendation-of-hold-from-brokerages.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply